Direkt zum Inhalt
Merck
  • [A sulfadiazine-tetroxoprim combination (co-tetroxazine) in the treatment of the acute exacerbation of chronic bronchitis].

[A sulfadiazine-tetroxoprim combination (co-tetroxazine) in the treatment of the acute exacerbation of chronic bronchitis].

Minerva medica (1988-07-01)
M G Gambaro, P Genoni, D Berra
ZUSAMMENFASSUNG

After considering the bacterial flora which is most common in relapses in patients with bronchitis, 40 patients with chronic bronchitis have been treated with tetroxoprim a recently synthetized benzyl pyrimidine associated with sulfadiazine. One 350 mg tablet was administered every 12 hours for different periods, from 7 to 14 days. This study has shown how tetroxoprim has a wide antibacterial range, how it is well tolerated and extremely powerful in treating relapses of chronic infections in bronchi.

MATERIALIEN
Produktnummer
Marke
Produktbeschreibung

Sigma-Aldrich
Sulfadiazin, 99.0-101.0%
Supelco
Sulfadiazin, Pharmaceutical Secondary Standard; Certified Reference Material
Supelco
Sulfadiazin, VETRANAL®, analytical standard
USP
Sulfadiazin, United States Pharmacopeia (USP) Reference Standard
Sulfadiazin, European Pharmacopoeia (EP) Reference Standard
Sulfadiazin für die Identifizierung von Unreinheit F, European Pharmacopoeia (EP) Reference Standard